Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial

AIMS: Thiazolidinediones are insulin sensitizers, and are associated with fluid retention and increased risk of heart failure (HF) in people with type 2 diabetes. We assessed fatal and non-fatal HF events and their outcome, and identified HF predictors in the RECORD (Rosiglitazone Evaluated for Card...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Komajda, Michel, McMurray, John J.V., Beck-Nielsen, Henning, Gomis, Ramon, Hanefeld, Markolf, Pocock, Stuart J., Curtis, Paula S., Jones, Nigel P., Home, Philip D.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2010
Témata:
Clinical Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2848325/
https://ncbi.nlm.nih.gov/pubmed/20118174
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehp604
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky